SME-3, a novel member of the Serratia marcescens SME family of carbapenem-hydrolyzing beta-lactamases.
Imipenem-resistant Serratia marcescens isolates were cultured from a lung transplant patient given multiple antibiotics over several months. The strains expressed SME-3, a beta-lactamase of the rare SME carbapenem-hydrolyzing family. SME-3 differed from SME-1 by a single amino acid substitution of tyrosine for histidine at position 105, but the two beta-lactamases displayed similar hydrolytic profiles.
Queenan
Anne Marie
AM
Antimicrobial Agents Research Team, Johnson & Johnson Pharmaceutical Research and Development, LLC, Raritan, NJ 08869, USA. aqueenan@prdus.jnj.com
Shang
Wenchi
W
Schreckenberger
Paul
P
Lolans
Karen
K
Bush
Karen
K
Quinn
John
J
D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000494:pharmacology*; D015780:Carbapenems / Q000378:metabolism* / Q000494:pharmacology; D006801:Humans; D015378:Imipenem / Q000378:metabolism / Q000494:pharmacology; D007700:Kinetics; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D016868:Serratia Infections / Q000382:microbiology; D012706:Serratia marcescens / Q000187:drug effects* / Q000201:enzymology*; D018440:beta-Lactam Resistance; D001618:beta-Lactamases / Q000145:classification / Q000235:genetics / Q000378:metabolism*
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D015378:Imipenem; D001618:beta-Lactamases